drugset
drugset / Trial / NCT06165146

A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants

NCT06165146 ↗

Phase 1 Completed 16 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
Non-randomizedSequentialOpen-labelBasic science

Summary

The main purpose of this study is to evaluate the effect of pirtobrutinib (LOXO-305) on single oral dose of repaglinide (CYP2C8 substrate) when administered as multiple doses by conducting the blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib (LOXO-305) in adult healthy participants. The study will also evaluate the safety and tolerability of pirtobrutinib (LOXO-305). The study is conducted in two periods. Participants will stay in this study for up to 54 days.

Timeline

Start
2020-11-10
Primary completion
2020-12-30
Completion
2020-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirtobrutinib Other / unclassified 200 mg Oral
Subject Repaglinide Small molecule 0.5 mg Oral

Indications

No indication recorded.